Resources

The United States is among the largest funders of global health. As part of a global organization with a footprint in 70+ countries, the PATH team in Washington, D.C. leverages technical expertise to equip decision-makers with the information and evidence needed to make smart global health policy. In particular, we work with policymakers to ensure that funding for global health matches the scale of the challenges we face around the world, and that US global health polices and strategies are evidence-informed, ambitious, accountable, and—most importantly—promote equitable access to health. This brief gives a high-level overview of PATH as an organization, our impact, and our footprint in the United States.

As part of the global response to the COVID-19 pandemic, there has been a proliferation of procurement options providing respiratory care equipment and related services to treat severe and critical COVID-19 patients. However, there is limited awareness of the various procurement options available to prospective buyers and how to utilize them.This summary brief highlights respiratory care equipment procurement options and organizations that play a pivotal role in financing, coordinating, and conducting such procurements. It aims to increase awareness of the various procurement options available to prospective respiratory care equipment buyers—such as public procurement entities at national and subnational levels, public and private health facilities, and nongovernmental organizations—in order to inform purchasing decisions. It also aims to strengthen coordination among the global respiratory care equipment community by increasing understanding of each organization’s offerings and capabilities.

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common enzyme deficiency that is prevalent in many malaria-endemic countries. G6PD-deficient individuals are susceptible to hemolysis when exposed to certain medications and food, including 8-aminoquinoline drugs (primaquine and newly introduced tafenoquine) used to fully treat Plasmodium vivax malaria patients by killing the malaria parasites that lie dormant in the liver. This is known as “radical cure.” As a result, the World Health Organization (WHO) recommends conducting a G6PD test prior to initiating radical cure treatment. A simple point-of-care (POC) test for G6PD deficiency enables wide-scale radical cure treatment of patients with P. vivax malaria and accelerates elimination of the disease.

With the sudden outbreak of the deadly COVID-19 pandemic that hit the world at the end of 2019, and the problems arising ever since, there is an urgent need for reliable and efficient laboratory tests to diagnose SARS-CoV-2, the virus that causes COVID-19. The crucial role played by laboratories in helping people obtain an accurate diagnosis and effective care has never been more evident than during the current pandemic.This document aims to provide complete and accessible information about COVID-19 and its diagnosis. Created especially for laboratory personnel and stakeholders involved in laboratory work, this “handbook” on COVID-19 Testing on COVID-19 testing includes guidance on various diagnostic techniques for COVID-19. Aside from providing basic information about COVID-19 testing techniques and biosafety measures, this report also covers information about the standard procedures needed to set up a COVID-19 laboratory and how to carry out validation and approval of test kits for COVID-19 using antigen rapid diagnostic tests (Ag-RDTs) and molecular diagnostics, like polymerase chain reaction (PCR).It is hoped that this document will act as a handy and useful guide for laboratory personnel involved in COVID-19 diagnosis.

The study aims to use a behaviour science and human centred design approach tounderstand the barriers to uptake of COVID-19 vaccines, and use this fundamentalunderstanding to design interventions to drive vaccine uptake